Evidence map›Paper›PMID 39495801›Full record

ArticlePloS one2024

COVID-19 vaccine uptake and associated factors among individuals living in a peri-urban area in Uganda: A cross-sectional study.

Mary Bridget Nanteza, Gertrude Nanyonjo, Nasimu Kyakuwa, Flavia Nakanjako, Hamza Kalute, Christine Atuhairwe, Christine Watera, Deogratius Ssemwanga

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mary Bridget NantezaExpanded Program on Immunization Laboratory, Uganda Virus Research Institute (UVRI), Entebbe, Uganda.
Gertrude NanyonjoUVRI-International AIDS Vaccine Initiative (UVRI-IAVI), Entebbe, Uganda.ORCID 0000-0002-1485-8222
Nasimu KyakuwaUVRI-International AIDS Vaccine Initiative (UVRI-IAVI), Entebbe, Uganda.ORCID 0000-0002-9671-1282
Flavia NakanjakoExpanded Program on Immunization Laboratory, Uganda Virus Research Institute (UVRI), Entebbe, Uganda.
Hamza KaluteExpanded Program on Immunization Laboratory, Uganda Virus Research Institute (UVRI), Entebbe, Uganda.
Christine AtuhairweFaculty of Health Sciences, Uganda Martyrs University, Kampala, Uganda.ORCID 0000-0002-8467-2802
Christine WateraExpanded Program on Immunization Laboratory, Uganda Virus Research Institute (UVRI), Entebbe, Uganda.
Deogratius SsemwangaExpanded Program on Immunization Laboratory, Uganda Virus Research Institute (UVRI), Entebbe, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Corona virus disease (COVID-19) is a respiratory illness that is caused by SARS-CoV-2 virus. This virus was first reported in China in December 2019. It then spread to all countries and from March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. In Uganda, the disease was first reported in March 2020 and COVID-19 vaccines became available by January 2021. Although COVID-19 vaccines were available in Uganda, uptake remained low. The aim of this study was to establish COVID-19 vaccine uptake awareness in a peri-urban setting in Entebbe City, Uganda.

methodsThis was a cross-sectional study conducted among 127 men and 263 women who reside in Entebbe City, Uganda. Data was collected on socio-behavioral characteristics, knowledge, attitude, and practice (KAP) about COVID-19 vaccine using interviewer administered questionnaires. Uptake of COVID-19 vaccine was defined as the proportion of participants who had received at least one dose of the COVID-19 vaccine. We used descriptive statistics to estimate awareness of COVID-19 vaccines. The 'chi-square test' and 'modified Poisson regression' were used to assess variations in uptake of COVID-19 vaccines among respondents and their socio-demographics as well as other characteristics.

resultsNinety-nine percent (388 out of 390) of the study population were aware of at least one brand of COVID-19 vaccines in the country. Thirty-five percent (138 out of 390) knew that the vaccine immunity was achieved 14 days after the 2nd dose and 98.7% (385 out of 390) admitted that observing the standard operating procedure for COVID-19 infection prevention was necessary after vaccination. There was a gap in knowledge on vaccine safety reported by 74.6% (291 out of 390) participants. Some participants 37.2% (145 out of 390) had concerns about the vaccine. Of these, 57.9% (84 out of 145) believed that the vaccines were not helpful; and 30.3% (44 out of 145) feared serious side effects. Sixty-six percent (257 out of 390) believed that vaccines were not working and 79.0% (308 out of 390) admitted that vaccines were promoted for financial gain. At the time of performing the study, 36.2% and 22.3% had received the 1st and 2nd dose respectively. The main sources of information on COVID-19 vaccine were television (TV) and social media (p-value 0.001). In a multivariate model, COVID-19 vaccine acceptability was associated with salaried and self-employment (p-value 0.046). The other predicative factors were awareness of the COVID-19 vaccine (p-value <0.001) and having vaccine concerns (p-value 0.013).

conclusionUptake of COVID-19 vaccination in Entebbe community was low, partly attributed to knowledge gaps and concerns about vaccine safety and effectiveness. This highlights the need to enhance dissemination of information about COVID-19 vaccine. The lessons learnt in this study would be relevant for other emerging infections by informing vaccination implementation programs in similar settings.

Indexed as

COVID-19COVID-19 VaccinesHealth Knowledge, Attitudes, PracticeAdolescentAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedSARS-CoV-2Surveys and QuestionnairesUgandaVaccinationYoung AdultCOVID-19 Vaccines

Identifiers

PMID39495801
PMCPMC11534251

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.